Aktis Oncology seeks to raise $212 million in Nasdaq IPO

Investing.com -- Aktis Oncology Inc., a clinical-stage biotechnology company developing radiopharmaceuticals for cancer treatment, plans to raise up to $212 million in its upcoming U.S. initial public offering.

The Boston-based company filed with the Securities and Exchange Commission on Monday to sell 11.8 million shares priced between $16 and $18 each. At the top of the pricing range, Aktis would reach a market value of approximately $840 million. Aktis plans to list its shares on Nasdaq under the ticker "AKTS."

The company has previously secured approximately $346 million from life-sciences investors. Major shareholders include MPM with a 26% stake before the IPO, Vida Ventures with 14%, EcoR1 Capital with 11%, and Blue Owl Capital with 7%.

Founded in 2021, Aktis specializes in targeted therapies using alpha-emitting radioactive agents to treat solid tumors. The company reported a net loss of $48.6 million on revenue of $4.6 million for the nine months ended September 30, compared to a net loss of $31.9 million on revenue of $554,000 during the same period a year earlier.

JPMorgan Chase & Co, Bank of America Corp., Leerink Partners and Toronto-Dominion Bank are serving as lead underwriters.

You May Also Be Interested In

• Oura IPO said to draw four times demand as orders near close
• IBG resolves Nasdaq filing issue but faces equity shortfall
• EquipmentShare disputes Blue Orca Capital short-seller report